01—Abstract
Summary
Summary of the 8-K filed May 27, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed a Form 8-K on May 27, 2026 under Item 8.01 (Other Events) to announce that the U.S. Food and Drug Administration accepted for filing its New Drug Application (NDA) for oral BBP-418 for the treatment of limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with Priority Review.
The FDA assigned a PDUFA target action date of November 27, 2026, and the company is poised to launch the drug upon approval. The FDA also indicated it is not currently planning to hold an advisory committee meeting to discuss the application. According to the attached press release (Exhibit 99.1), BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis of the Phase 3 FORTIFY trial, with treated individuals improving while placebo recipients declined on every key measure.
The company states that, if approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD. BBP-418 has already received Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from the European Medicines Agency; BridgeBio may qualify for a Priority Review Voucher if approved. The filing is primarily a regulatory milestone disclosure and contains no financial figures.
The filing does not provide commercial projections, revenue estimates, or financial guidance. The company also states it is engaging regulatory agencies to identify an expedited path to approval in Europe and intends to initiate clinical studies in younger patients and in related LGMD subtypes.
02—Key points
Key Highlights
- FDA accepted the NDA for oral BBP-418 for LGMD2I/R9 with Priority Review, with a PDUFA target action date of November 27, 2026.
- The FDA indicated it is not currently planning to hold an advisory committee meeting to discuss the application.
- Phase 3 FORTIFY trial met all primary and secondary endpoints at the pre-specified 12-month interim analysis, with treated individuals improving while placebo recipients declined.
- If approved, BBP-418 would be the first and only therapy for LGMD2I/R9 and the first approved treatment for any form of LGMD, per the company.
- BBP-418 holds Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from the EMA.
- BridgeBio may qualify for a Priority Review Voucher if BBP-418 is approved, consistent with its Rare Pediatric Disease Designation.
- The company is poised to launch BBP-418 upon approval and is engaging regulators on an expedited European path.
03—Questions
Frequently Asked Questions
What is the key regulatory date for BBP-418?
The FDA assigned a PDUFA target action date of November 27, 2026 for the NDA for BBP-418 in LGMD2I/R9.
Will there be an advisory committee meeting for BBP-418?
The FDA notified the company that it is not currently planning to hold an advisory committee meeting to discuss the application.
What efficacy data supports the application?
The company reports that BBP-418 met all primary and secondary endpoints at the pre-specified 12-month interim analysis of the Phase 3 FORTIFY trial, with treated individuals improving on every key measure while placebo recipients declined. Results were presented as a late-breaking oral presentation at the 2026 MDA Clinical and Scientific Conference.
Could BBP-418 receive a Priority Review Voucher?
The company states that, consistent with the Rare Pediatric Disease Designation, BridgeBio may qualify for a Priority Review Voucher if BBP-418 is approved.
What are the company's next steps beyond the U.S. approval?
The company is engaging regulatory agencies to identify an expedited path to approval in Europe and intends to initiate clinical studies of BBP-418 in individuals under 12 years of age and in LGMD2M/R13 and LGMD2U/R20 in the near future.
04—Continue